Wells Fargo & Company Tarsus Pharmaceuticals, Inc. Call Options Transaction History
Wells Fargo & Company
- $407 Billion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding TARS
# of Institutions
160Shares Held
41.1MCall Options Held
37.9KPut Options Held
808K-
Rtw Investments, LP New York, NY3.41MShares$160 Million1.55% of portfolio
-
Black Rock Inc. New York, NY3.27MShares$153 Million0.0% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY2.44MShares$114 Million2.68% of portfolio
-
Tang Capital Management LLC San Diego, CA2.25MShares$106 Million7.48% of portfolio
-
Cowen And Company, LLC2.2MShares$103 Million1.53% of portfolio
About Tarsus Pharmaceuticals, Inc.
- Ticker TARS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 26,658,500
- Market Cap $1.25B
- Description
- Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as...